Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
116 hedge funds and large institutions have $287M invested in Five Prime Therapeutics, Inc. in 2018 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 38 reducing their positions, and 16 closing their positions.
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
2% more funds holding
Funds holding: 114 → 116 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 38
33% less capital invested
Capital invested by funds: $430M → $287M (-$142M)
82% less call options, than puts
Call options by funds: $156K | Put options by funds: $858K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$8.93M |
| 2 |
Man Group
London,
United Kingdom
|
+$6.15M |
| 3 |
Axa
Paris,
France
|
+$4.36M |
| 4 |
Renaissance Technologies
New York
|
+$3.97M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.8M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$7.14M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.83M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.91M |
| 5 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$3.25M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
126
Prelude Capital Management
New York
| – | -$13K | -906 | Closed |
|
|
TRCT
127
Tower Research Capital (TRC)
New York
| – | -$4K | -296 | Closed |
|
|
SFG
128
SevenBridge Financial Group
Harrisburg,
Pennsylvania
| – | -$3K | -200 | Closed |
|
|
PCG
129
Private Capital Group
West Hartford,
Connecticut
| – | -$1K | -140 | Closed |
|
130
US Bancorp
Minneapolis,
Minnesota
| – | -$773 | -65 | -87% |
|
131
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$226 | -19 | -43% |
|
FPRX Hedge Fund Activity: Q4 2018 in Review
116 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q4 2018, worth a combined $287M — down 33% from $430M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new FPRX positions and 16 closed out — a net gain of 2 holders — while 34 added to existing stakes and 38 trimmed.
The largest buyer was Great Point Partners, adding an estimated $8.93M. The largest seller was Vanguard Group, cutting an estimated $10.8M.
- 116 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q4 2018, up from 114 in Q3 2018.
- Funds reported $287M of Five Prime Therapeutics, Inc. stock for Q4 2018, down 33% quarter-over-quarter.
- 18 funds opened new Five Prime Therapeutics, Inc. positions in Q4 2018 and 16 closed out, a net change of +2 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q4 2018 was Great Point Partners, an estimated $8.93M added.
- The largest Five Prime Therapeutics, Inc. seller in Q4 2018 was Vanguard Group, an estimated $10.8M sold.
Based on aggregated 13F filings for Q4 2018.